{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:05:02Z","timestamp":1792641902864,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62926-0","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:54:45Z","timestamp":1758797685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Autonomous artificial intelligence prescribing a drug to prevent severe acute graft-versus-host disease in HLA-haploidentical transplants"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3691-4931","authenticated-orcid":false,"given":"Junren","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9097-8103","authenticated-orcid":false,"given":"Yigeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saibing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-894X","authenticated-orcid":false,"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieya","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sichang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangsong","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5551-9721","authenticated-orcid":false,"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-6495","authenticated-orcid":false,"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-6348","authenticated-orcid":false,"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-6799","authenticated-orcid":false,"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-3446","authenticated-orcid":false,"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-6063","authenticated-orcid":false,"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"62926_CR1","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2589-7500(20)30187-4","volume":"2","author":"DS Bitterman","year":"2020","unstructured":"Bitterman, D. S., Aerts, H. & Mak, R. H. Approaching autonomy in medical artificial intelligence. Lancet Digit Health 2, e447\u2013e449 (2020).","journal-title":"Lancet Digit Health"},{"key":"62926_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41591-021-01359-w","volume":"27","author":"C McIntosh","year":"2021","unstructured":"McIntosh, C. et al. Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. Nat. Med 27, 999\u20131005 (2021).","journal-title":"Nat. Med"},{"key":"62926_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.brachy.2020.03.004","volume":"19","author":"A Nicolae","year":"2020","unstructured":"Nicolae, A. et al. Conventional vs machine learning-based treatment planning in prostate brachytherapy: Results of a Phase I randomized controlled trial. Brachytherapy 19, 470\u2013476 (2020).","journal-title":"Brachytherapy"},{"key":"62926_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01831-4","volume":"16","author":"J Wong","year":"2021","unstructured":"Wong, J. et al. Implementation of deep learning-based auto-segmentation for radiotherapy planning structures: a workflow study at two cancer centers. Radiat. Oncol. 16, 101 (2021).","journal-title":"Radiat. Oncol."},{"key":"62926_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41746-021-00539-9","volume":"4","author":"A Hassoon","year":"2021","unstructured":"Hassoon, A. et al. Randomized trial of two artificial intelligence coaching interventions to increase physical activity in cancer survivors. NPJ Digit Med. 4, 168 (2021).","journal-title":"NPJ Digit Med"},{"key":"62926_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41746-023-00931-7","volume":"6","author":"MD Abramoff","year":"2023","unstructured":"Abramoff, M. D. et al. Autonomous artificial intelligence increases real-world specialist clinic productivity in a cluster-randomized trial. NPJ Digit Med. 6, 184 (2023).","journal-title":"NPJ Digit Med"},{"key":"62926_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamaoncol.2022.6303","volume":"9","author":"CR Manz","year":"2023","unstructured":"Manz, C. R. et al. Long-term effect of machine learning-triggered behavioral nudges on serious illness conversations and end-of-life outcomes among patients with cancer: a randomized clinical trial. JAMA Oncol. 9, 414\u2013418 (2023).","journal-title":"JAMA Oncol."},{"key":"62926_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44676-z","volume":"15","author":"RM Wolf","year":"2024","unstructured":"Wolf, R. M. et al. Autonomous artificial intelligence increases screening and follow-up for diabetic retinopathy in youth: the ACCESS randomized control trial. Nat. Commun. 15, 421 (2024).","journal-title":"Nat. Commun."},{"key":"62926_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41746-024-01389-x","volume":"7","author":"MD Abramoff","year":"2024","unstructured":"Abramoff, M. D. et al. Mitigation of AI adoption bias through an improved autonomous AI system for diabetic retinal disease. NPJ Digit Med. 7, 369 (2024).","journal-title":"NPJ Digit Med"},{"key":"62926_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2024.01.044","volume":"167","author":"R Djinbachian","year":"2024","unstructured":"Djinbachian, R. et al. Autonomous artificial intelligence vs artificial intelligence-assisted human optical diagnosis of colorectal polyps: a randomized controlled trial. Gastroenterology 167, 392\u2013399 e392 (2024).","journal-title":"Gastroenterology"},{"key":"62926_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102692","volume":"73","author":"E Meinert","year":"2024","unstructured":"Meinert, E. et al. Accuracy and safety of an autonomous artificial intelligence clinical assistant conducting telemedicine follow-up assessment for cataract surgery. EClinicalMedicine 73, 102692 (2024).","journal-title":"EClinicalMedicine"},{"key":"62926_CR12","doi-asserted-by":"publisher","first-page":"e000255","DOI":"10.1136\/bmjonc-2023-000255","volume":"3","author":"S Macheka","year":"2024","unstructured":"Macheka, S. et al. Prospective evaluation of artificial intelligence (AI) applications for use in cancer pathways following diagnosis: a systematic review. BMJ Oncol. 3, e000255 (2024).","journal-title":"BMJ Oncol."},{"key":"62926_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ng.3756","volume":"49","author":"M Gerstung","year":"2017","unstructured":"Gerstung, M. et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat. Genet 49, 332\u2013340 (2017).","journal-title":"Nat. Genet"},{"key":"62926_CR14","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/s41591-018-0213-5","volume":"24","author":"M Komorowski","year":"2018","unstructured":"Komorowski, M., Celi, L. A., Badawi, O., Gordon, A. C. & Faisal, A. A. The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nat. Med. 24, 1716\u20131720 (2018).","journal-title":"Nat. Med"},{"key":"62926_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-021-01118-x","volume":"14","author":"M Bill","year":"2021","unstructured":"Bill, M. et al. Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. J. Hematol. Oncol. 14, 107 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"62926_CR16","doi-asserted-by":"publisher","first-page":"102461","DOI":"10.1016\/j.ipm.2020.102461","volume":"58","author":"H Yang","year":"2021","unstructured":"Yang, H., Guo, X., Peng, Z. & Lai, K.-H. The antecedents of effective use of hospital information systems in the chinese context: A mixed-method approach. Inf. Process Manag. 58, 102461 (2021).","journal-title":"Inf. Process Manag"},{"key":"62926_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.bbmt.2015.12.024","volume":"22","author":"A El-Jawahri","year":"2016","unstructured":"El-Jawahri, A. et al. Improved treatment-related mortality and overall survival of patients with grade IV acute GVHD in the modern years. Biol. Blood Marrow Transpl. 22, 910\u2013918 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"62926_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s43588-022-00213-4","volume":"2","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Dynamic forecasting of severe acute graft-versus-host disease after transplantation. Nat. Comput Sci. 2, 153\u2013159 (2022).","journal-title":"Nat. Comput Sci."},{"key":"62926_CR19","doi-asserted-by":"publisher","unstructured":"Chen, J., Qi, S., Feng, Y., Wang, Y. & Cui, M. daGOAT (v2.0). Zenodo, https:\/\/doi.org\/10.5281\/zenodo.14898554 (2025).","DOI":"10.5281\/zenodo.14898554"},{"key":"62926_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-024-08264-5","volume":"637","author":"BH Foy","year":"2025","unstructured":"Foy, B. H. et al. Haematological setpoints are a stable and patient-specific deep phenotype. Nature 637, 430\u2013438 (2025).","journal-title":"Nature"},{"key":"62926_CR21","doi-asserted-by":"publisher","first-page":"e1149","DOI":"10.1111\/aos.14132","volume":"97","author":"A Grzybowski","year":"2019","unstructured":"Grzybowski, A. & Brona, P. A pilot study of autonomous artificial intelligence-based diabetic retinopathy screening in Poland. Acta Ophthalmol. 97, e1149\u2013e1150 (2019).","journal-title":"Acta Ophthalmol."},{"key":"62926_CR22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2337\/dc20-1671","volume":"44","author":"RM Wolf","year":"2021","unstructured":"Wolf, R. M. et al. The SEE study: safety, efficacy, and equity of implementing autonomous artificial intelligence for diagnosing diabetic retinopathy in youth. Diab. Care 44, 781\u2013787 (2021).","journal-title":"Diab. Care"},{"key":"62926_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41433-021-01912-4","volume":"36","author":"A Sedova","year":"2022","unstructured":"Sedova, A. et al. Comparison of early diabetic retinopathy staging in asymptomatic patients between autonomous AI-based screening and human-graded ultra-widefield colour fundus images. Eye (Lond.) 36, 510\u2013516 (2022).","journal-title":"Eye (Lond.)"},{"key":"62926_CR24","first-page":"2","volume":"5","author":"B Nolan","year":"2023","unstructured":"Nolan, B., Daybranch, E. R., Barton, K. & Korsen, N. Patient and provider experience with artificial intelligence screening technology for diabetic retinopathy in a rural primary care setting. J. Maine Med Cent. 5, 2 (2023).","journal-title":"J. Maine Med Cent."},{"key":"62926_CR25","doi-asserted-by":"publisher","unstructured":"Bhambhwani, V. et al. Feasibility and patient experience of a pilot artificial intelligence-based diabetic retinopathy screening program in Northern Ontario. Ophthalmic Epidemiol. https:\/\/doi.org\/10.1080\/09286586.2024.2434738 (2024).","DOI":"10.1080\/09286586.2024.2434738"},{"key":"62926_CR26","doi-asserted-by":"publisher","first-page":"e0190610","DOI":"10.1371\/journal.pone.0190610","volume":"13","author":"C Lee","year":"2018","unstructured":"Lee, C. et al. Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. PLoS One 13, e0190610 (2018).","journal-title":"PLoS One"},{"key":"62926_CR27","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1182\/bloodadvances.2019000934","volume":"3","author":"Y Arai","year":"2019","unstructured":"Arai, Y. et al. Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. Blood Adv. 3, 3626\u20133634 (2019).","journal-title":"Blood Adv."},{"key":"62926_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMoa1213299","volume":"369","author":"MT Vander Lugt","year":"2013","unstructured":"Vander Lugt, M. T. et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N. Engl. J. Med. 369, 529\u2013539 (2013).","journal-title":"N. Engl. J. Med"},{"key":"62926_CR29","first-page":"2771","volume":"141","author":"G Socie","year":"2023","unstructured":"Socie, G. et al. Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis. Blood 141, 2771\u20132779 (2023).","journal-title":"Blood"},{"key":"62926_CR30","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/bloodadvances.2023012091","volume":"8","author":"Y Akahoshi","year":"2024","unstructured":"Akahoshi, Y. et al. Flares of acute graft-versus-host disease: a mount sinai acute GVHD international consortium analysis. Blood Adv. 8, 2047\u20132057 (2024).","journal-title":"Blood Adv."},{"key":"62926_CR31","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1182\/bloodadvances.2024012561","volume":"8","author":"Z DeFilipp","year":"2024","unstructured":"DeFilipp, Z. et al. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD. Blood Adv. 8, 3488\u20133496 (2024).","journal-title":"Blood Adv."},{"key":"62926_CR32","first-page":"128","volume":"4","author":"S Tang","year":"2020","unstructured":"Tang, S. et al. Predicting acute graft-versus-host disease using machine learning and longitudinal vital sign data from electronic health records. JCO Clin. Cancer Inf. 4, 128\u2013135 (2020).","journal-title":"JCO Clin. Cancer Inf."},{"key":"62926_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43372-2","volume":"14","author":"E Bayraktar","year":"2023","unstructured":"Bayraktar, E. et al. Data-driven grading of acute graft-versus-host disease. Nat. Commun. 14, 7799 (2023).","journal-title":"Nat. Commun."},{"key":"62926_CR34","doi-asserted-by":"publisher","first-page":"299ra122","DOI":"10.1126\/scitranslmed.aab3719","volume":"7","author":"KE Henry","year":"2015","unstructured":"Henry, K. E., Hager, D. N., Pronovost, P. J. & Saria, S. A targeted real-time early warning score (TREWScore) for septic shock. Sci. Transl. Med 7, 299ra122 (2015).","journal-title":"Sci. Transl. Med"},{"key":"62926_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.35","volume":"3","author":"AE Johnson","year":"2016","unstructured":"Johnson, A. E. et al. MIMIC-III, a freely accessible critical care database. Sci. Data 3, 160035 (2016).","journal-title":"Sci. Data"},{"key":"62926_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41591-020-0789-4","volume":"26","author":"SL Hyland","year":"2020","unstructured":"Hyland, S. L. et al. Early prediction of circulatory failure in the intensive care unit using machine learning. Nat. Med. 26, 364\u2013373 (2020).","journal-title":"Nat. Med"},{"key":"62926_CR37","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.bbmt.2020.05.001","volume":"26","author":"A Im","year":"2020","unstructured":"Im, A. et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol. Blood Marrow Transpl. 26, 1459\u20131468 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"62926_CR38","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3324\/haematol.2020.247296","volume":"106","author":"A Nagler","year":"2021","unstructured":"Nagler, A. et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica 106, 1591\u20131598 (2021).","journal-title":"Haematologica"},{"key":"62926_CR39","first-page":"587 e581","volume":"28","author":"G Battipaglia","year":"2022","unstructured":"Battipaglia, G. et al. Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone in acute myelogenous leukemia: a retrospective study on behalf of the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Transpl. Cell Ther. 28, 587 e581\u2013587.e587 (2022).","journal-title":"Transpl. Cell Ther."},{"key":"62926_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-023-01403-x","volume":"16","author":"F Baron","year":"2023","unstructured":"Baron, F. et al. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT. J. Hematol. Oncol. 16, 10 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"62926_CR41","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1200\/JCO.23.00101","volume":"41","author":"Y Ling","year":"2023","unstructured":"Ling, Y. et al. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide for AML Undergoing HLA-haploidentical hematopoietic cell transplantation: a multicenter randomized phase III Trial. J. Clin. Oncol. 41, 4632\u20134642 (2023).","journal-title":"J. Clin. Oncol."},{"key":"62926_CR42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41409-023-01980-y","volume":"58","author":"A Nagler","year":"2023","unstructured":"Nagler, A. et al. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP\/EBMT. Bone Marrow Transpl. 58, 791\u2013800 (2023).","journal-title":"Bone Marrow Transpl."},{"key":"62926_CR43","first-page":"377 e371","volume":"29","author":"RS Mehta","year":"2023","unstructured":"Mehta, R. S. et al. Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transpl. Cell Ther. 29, 377 e371\u2013377.e377 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"62926_CR44","doi-asserted-by":"publisher","first-page":"e920","DOI":"10.1097\/HS9.0000000000000920","volume":"7","author":"MA Kharfan-Dabaja","year":"2023","unstructured":"Kharfan-Dabaja, M. A. et al. Significance of degree of HLA disparity using T-cell replete peripheral blood stem cells from haploidentical donors with posttransplantation cyclophosphamide in AML in first complete hematologic remission: a study of the acute leukemia working party of the EBMT. Hemasphere 7, e920 (2023).","journal-title":"Hemasphere"},{"key":"62926_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-023-01421-9","volume":"16","author":"Y Ye","year":"2023","unstructured":"Ye, Y. et al. Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the global committee and the acute leukemia working party of the European Society For Blood And Marrow Transplantation. J. Hematol. Oncol. 16, 25 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"62926_CR46","first-page":"184 e181","volume":"29","author":"A Mussetti","year":"2023","unstructured":"Mussetti, A. et al. Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas. Transpl. Cell Ther. 29, 184 e181\u2013184.e189 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"62926_CR47","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s00277-023-05324-0","volume":"102","author":"WJ Yu","year":"2023","unstructured":"Yu, W. J. et al. Comparison of outcomes for patients with acute myeloid leukemia undergoing haploidentical stem cell transplantation in first and second complete remission. Ann. Hematol. 102, 2241\u20132250 (2023).","journal-title":"Ann. Hematol."},{"key":"62926_CR48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12185-023-03693-w","volume":"119","author":"K Fukunaga","year":"2024","unstructured":"Fukunaga, K. et al. HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analysis. Int J. Hematol. 119, 173\u2013182 (2024).","journal-title":"Int J. Hematol."},{"key":"62926_CR49","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"AH Bazarbachi","year":"2024","unstructured":"Bazarbachi, A. H. et al. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: a report from the European Society For Blood And Marrow Transplantation Acute Leukemia Working Party. Cancer 130, 3123\u20133136 (2024).","journal-title":"Cancer"},{"key":"62926_CR50","first-page":"229 e221","volume":"30","author":"H Elmariah","year":"2024","unstructured":"Elmariah, H. et al. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide. Transpl. Cell Ther. 30, 229 e221\u2013229.e211 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"62926_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41409-023-02142-w","volume":"59","author":"Y Shimomura","year":"2024","unstructured":"Shimomura, Y. et al. Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide. Bone Marrow Transpl. 59, 66\u201375 (2024).","journal-title":"Bone Marrow Transpl."},{"key":"62926_CR52","first-page":"903 e901","volume":"30","author":"SR Solomon","year":"2024","unstructured":"Solomon, S. R. et al. Impact of graft-versus-host disease on relapse and nonrelapse mortality following posttransplant cyclophosphamide-based transplantation. Transpl. Cell Ther. 30, 903 e901\u2013903.e909 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"62926_CR53","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bjh.19228","volume":"204","author":"S Fuji","year":"2024","unstructured":"Fuji, S. et al. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br. J. Haematol. 204, 959\u2013966 (2024).","journal-title":"Br. J. Haematol."},{"key":"62926_CR54","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41409-024-02400-5","volume":"59","author":"A Nagler","year":"2024","unstructured":"Nagler, A. et al. Young (<35 years) haploidentical versus old (>\/=35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 59, 1552\u20131562 (2024).","journal-title":"Bone Marrow Transpl."},{"key":"62926_CR55","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/bjh.19825","volume":"205","author":"M Moriguchi","year":"2024","unstructured":"Moriguchi, M. et al. Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia. Br. J. Haematol. 205, 2376\u20132386 (2024).","journal-title":"Br. J. Haematol."},{"key":"62926_CR56","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41746-024-01275-6","volume":"7","author":"A Subbaswamy","year":"2024","unstructured":"Subbaswamy, A. et al. A data-driven framework for identifying patient subgroups on which an AI\/machine learning model may underperform. NPJ Digit Med. 7, 334 (2024).","journal-title":"NPJ Digit Med"},{"key":"62926_CR57","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood.2020005957","volume":"136","author":"J Norona","year":"2020","unstructured":"Norona, J. et al. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. Blood 136, 1442\u20131455 (2020).","journal-title":"Blood"},{"key":"62926_CR58","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41591-024-03397-6","volume":"31","author":"R Mathias","year":"2025","unstructured":"Mathias, R. et al. Safe AI-enabled digital health technologies need built-in open feedback. Nat. Med. 31, 370\u2013375 (2025).","journal-title":"Nat. Med"},{"key":"62926_CR59","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1038\/s41409-021-01431-6","volume":"56","author":"LP Xu","year":"2021","unstructured":"Xu, L. P. et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transpl. 56, 2940\u20132947 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"62926_CR60","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans, H. M. et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 53, 1401\u20131415 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"62926_CR61","doi-asserted-by":"crossref","unstructured":"Cover T. M., Thomas J. A. Elements of Information Theory, 2nd Edition. John Wiley (2006).","DOI":"10.1002\/047174882X"},{"key":"62926_CR62","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser, R. et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N. Engl. J. Med. 382, 1800\u20131810 (2020).","journal-title":"N. Engl. J. Med"},{"key":"62926_CR63","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka, D. et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist 25, e328\u2013e334 (2020).","journal-title":"Oncologist"},{"key":"62926_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-024-02483-0","volume":"60","author":"V Escamilla-Gomez","year":"2025","unstructured":"Escamilla-Gomez, V. et al. Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC. Bone Marrow Transpl. 60, 353\u2013362 (2025).","journal-title":"Bone Marrow Transpl."},{"key":"62926_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88080-3","volume":"11","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia. Sci. Rep. 11, 8501 (2021).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62926-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:02:17Z","timestamp":1758801737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62926-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62926"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62926-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to Antengene Biotech LLC\u00a0and Shenzhen TargetRx; Medical Director, FFF Enterprises Inc.; a speaker for Janssen Pharma, BeiGene, and Hengrui Pharma; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board, StemRad Ltd. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8391"}}